|
Published by: Global Markets Direct
Published: Jun. 28, 2012 - 44 Pages
Table of Contents- Introduction
Global Markets Direct Report Coverage - House Dust Mite Allergy Overview
- Therapeutics Development
- An Overview of Pipeline Products for House Dust Mite Allergy
- House Dust Mite Allergy Therapeutics under Development by Companies
- Late Stage Products
- Comparative Analysis
- Mid Clinical Stage Products
- Comparative Analysis
- Early Clinical Stage Products
- Comparative Analysis
- Discovery and Pre-Clinical Stage Products
- Comparative Analysis
- House Dust Mite Allergy Therapeutics – Products under Development by Companies
- Companies Involved in House Dust Mite Allergy Therapeutics Development
- ALK-Abello A/S
- Stallergenes S.A.
- Allergopharma Joachim Ganzer KG
- Circassia Holdings Ltd.
- ImVisioN Therapeutics AG
- Genetic Immunity, LLC
- Biomay AG
- House Dust Mite Allergy – Therapeutics Assessment
- Assessment by Monotherapy Products
- Assessment by Route of Administration
- Assessment by Molecule Type
- Drug Profiles
- ToleroMune House Dust Mite T Cell Vaccine - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- Mitizax - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- ACTAIR - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- Acaroid - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- IVN-Mite - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- DermAll Vaccine - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- House Dust Mite Peptide Carrier Fusion Vaccine - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- House Dust Mite RNA Vaccine - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- House Dust Mite Hypoallergenic Vaccine - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- House Dust Mite Allergy Therapeutics – Drug Profile Updates
- Appendix
Methodology - Coverage
- Secondary Research
- Primary Research
- Expert Panel Validation
- Contact Us
- Disclaimer
- List of Tables
- Number of Products Under Development for House Dust Mite Allergy, H1 2012
- Products under Development for House Dust Mite Allergy – Comparative Analysis, H1 2012
- Number of Products under Development by Companies, H1 2012
- Comparative Analysis by Late Stage Development, H1 2012
- Comparative Analysis by Mid Clinical Stage Development, H1 2012
- Comparative Analysis by Early Clinical Stage Development, H1 2012
- Comparative Analysis by Discovery and Pre-Clinical Stage Development, H1 2012
- Products under Development by Companies, H1 2012
- ALK-Abello A/S, H1 2012
- Stallergenes S.A., H1 2012
- Allergopharma Joachim Ganzer KG, H1 2012
- Circassia Holdings Ltd., H1 2012
- ImVisioN Therapeutics AG, H1 2012
- Genetic Immunity, LLC, H1 2012
- Biomay AG, H1 2012
- Assessment by Monotherapy Products, H1 2012
- Assessment by Stage and Route of Administration, H1 2012
- Assessment by Stage and Molecule Type, H1 2012
- House Dust Mite Allergy Therapeutics – Drug Profile Updates
- List of Figures
- Number of Products under Development for House Dust Mite Allergy, H1 2012
- Products under Development for House Dust Mite Allergy – Comparative Analysis, H1 2012
- Products under Development by Companies, H1 2012
- Late Stage Products, H1 2012
- Mid Clinical Stage Products, H1 2012
- Early Clinical Stage Products, H1 2012
- Discovery and Pre-Clinical Stage Products, H1 2012
- Assessment by Monotherapy Products, H1 2012
- Assessment by Route of Administration, H1 2012
- Assessment by Stage and Route of Administration, H1 2012
- Assessment by Molecule Type, H1 2012
- Assessment by Stage and Molecule Type, H1 2012
AbstractHouse Dust Mite Allergy – Pipeline Review, H1 2012
Summary
Global Markets Direct’s, 'House Dust Mite Allergy - Pipeline Review, H1 2012', provides an overview of the House Dust Mite Allergy therapeutic pipeline. This report provides information on the therapeutic development for House Dust Mite Allergy, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for House Dust Mite Allergy. 'House Dust Mite Allergy - Pipeline Review, H1 2012' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope- A snapshot of the global therapeutic scenario for House Dust Mite Allergy.
- A review of the House Dust Mite Allergy products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the House Dust Mite Allergy pipeline on the basis of route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.
Reasons to buy- Identify and understand important and diverse types of therapeutics under development for House Dust Mite Allergy.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding House Dust Mite Allergy pipeline depth and focus of House Dust Mite Allergy therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
Get full details about this report >>
|
US: 800.298.5699
Int'l: +1.240.747.3093
|
|
|
About MarketResearch.com
MarketResearch.com is an online aggregator selling over 400,000 market research reports,
company profiles and country profiles from over 720 research firms. Our reports will
provide you with the critical business and competitive intelligence you need for strategic planning and marketing
research. Coverage includes the US, UK, Europe, Asia and global markets.
|
